Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lalan S Wilfong

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
JCO Oncology Practice|November 14, 2023
Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative TreatmentsEdgardo S Santos, Thomas K Oliver, Christina Lacchetti, et al.
JCO Oncology Practice|August 18, 2021
Secret Sauce-How Diverse Practices Succeed in Centers for Medicare & Medicaid Services Oncology Care ModelRonald M Kline, Sibel Blau, Nikolas R Buescher, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2011
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinomaAna De Jesus-Acosta, George R Oliver, Amanda Blackford, et al.
Investigational New Drugs|August 29, 2009
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative studyDonald A Richards, Paul R Kuefler, Carlos Becerra, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
JCO Oncology Practice|November 14, 2023
Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative TreatmentsEdgardo S Santos, Thomas K Oliver, Christina Lacchetti, et al.
JCO Oncology Practice|August 18, 2021
Secret Sauce-How Diverse Practices Succeed in Centers for Medicare & Medicaid Services Oncology Care ModelRonald M Kline, Sibel Blau, Nikolas R Buescher, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2011
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinomaAna De Jesus-Acosta, George R Oliver, Amanda Blackford, et al.
Investigational New Drugs|August 29, 2009
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative studyDonald A Richards, Paul R Kuefler, Carlos Becerra, et al.
Pageof 1